Exvade Bioscience Inc.
Atlanta, GA
- UEI
- MQ3GFMJ3LV85
- CAGE
- 95VL0
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 380 Northyards Blvd NW, Atlanta, GA 30313, USA
- Website
- exvadebio.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Tumor monorail device for serial glioblastoma biopsy | National Cancer Institute (NIH) | $4,396,335 |
Quick answers
Is Exvade Bioscience Inc. registered in SAM.gov?
Yes. Exvade Bioscience Inc.'s SAM.gov registration is active through March 6, 2027.
What is Exvade Bioscience Inc.'s most recent federal award?
Exvade Bioscience Inc.'s most recent federal grant award is Tumor monorail device for serial glioblastoma biopsy (R44CA285039), from National Cancer Institute (NIH), on August 1, 2023.
On GovTribe
See Exvade Bioscience Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors